The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Future perspectives on CAR-T therapy for multiple myeloma
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, highlights some of the ongoing research in CAR-T therapy for multiple myeloma including increasing capacity and speed of production, as well as increasing expression of BCMA, and a new target being currently evaluated – GPRC5D. Prof. Munshi also notes that some patients treated with CAR-T are benefiting from longer-term maintenance, potentially paving the way for a cure in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT
Scientific Founder: Oncopep, DCT
